Edwards Lifesciences Corp
EW81.194USD
-0.296-0.36%
交易中 （美東）報價延遲15分鐘
47.15B總市值
34.58本益比TTM
關於 Edwards Lifesciences Corp 公司
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Edwards Lifesciences Corp簡介
公司代碼EW
公司名稱Edwards Lifesciences Corp
上市日期Mar 27, 2000
CEOZovighian (Bernard J)
員工數量15800
證券類型Ordinary Share
年結日Mar 27
公司地址One Edwards Way
城市IRVINE
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編92614
電話19492502500
網址https://www.edwards.com
公司代碼EW
上市日期Mar 27, 2000
CEOZovighian (Bernard J)
Edwards Lifesciences Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
收入明細
單位: USD更新時間: 1月6日 週二
單位: USD更新時間: 1月6日 週二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
業務USD
名稱
營收
佔比
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
地區USD
名稱
營收
佔比
United States
907.50M
58.43%
Europe
387.90M
24.98%
Rest of the world
167.60M
10.79%
Japan
90.10M
5.80%
業務
地區
業務USD
名稱
營收
佔比
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
股東統計
更新時間: 1月10日 週六
更新時間: 1月10日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
其他
71.62%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
其他
71.62%
股東類型
持股股東
佔比
Investment Advisor
46.83%
Investment Advisor/Hedge Fund
30.96%
Hedge Fund
3.47%
Pension Fund
2.27%
Research Firm
2.17%
Bank and Trust
1.96%
Sovereign Wealth Fund
1.37%
Individual Investor
0.93%
Endowment Fund
0.83%
其他
9.21%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
2452
517.66M
93.53%
--
2025Q3
2537
517.80M
94.00%
-1.50M
2025Q2
2614
519.17M
94.35%
-5.19M
2025Q1
2599
525.51M
93.66%
-25.15M
2024Q4
2585
522.16M
89.45%
+17.15M
2024Q3
2546
504.88M
87.53%
-10.03M
2024Q2
2541
515.71M
87.77%
+1.93M
2024Q1
2555
513.21M
86.74%
-8.92M
2023Q4
2556
503.19M
87.55%
-12.35M
2023Q3
2509
516.79M
88.03%
-521.37K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
70.09M
12.08%
+359.01K
+0.51%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
30.52M
5.26%
-370.16K
-1.20%
Sep 30, 2025
State Street Investment Management (US)
25.62M
4.41%
-14.75K
-0.06%
Sep 30, 2025
Wellington Management Company, LLP
20.80M
3.59%
+977.93K
+4.93%
Sep 30, 2025
JP Morgan Asset Management
17.92M
3.09%
-2.17M
-10.80%
Sep 30, 2025
Jennison Associates LLC
13.96M
2.41%
+2.29M
+19.60%
Sep 30, 2025
Fidelity Management & Research Company LLC
13.03M
2.25%
+10.73M
+466.56%
Sep 30, 2025
Geode Capital Management, L.L.C.
12.84M
2.21%
+114.73K
+0.90%
Sep 30, 2025
Walter Scott & Partners Ltd.
9.96M
1.72%
+1.05M
+11.73%
Sep 30, 2025
Union Investment Privatfonds GmbH
8.60M
1.48%
+19.17K
+0.22%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares U.S. Medical Devices ETF
4.72%
Future Fund Long/Short ETF
3.86%
iShares Health Innovation Active ETF
3.65%
Global X Aging Population ETF
3.31%
Acruence Active Hedge US Equity ETF
2.58%
First Trust Indxx Medical Devices ETF
2.23%
State Street SPDR S&P Health Care Equipment ETF
1.88%
JPMorgan Healthcare Leaders ETF
1.8%
PGIM Jennison Better Future ETF
1.78%
ROBO Global Healthcare Technology & Innovation ETF
1.73%
查看更多
iShares U.S. Medical Devices ETF
佔比4.72%
Future Fund Long/Short ETF
佔比3.86%
iShares Health Innovation Active ETF
佔比3.65%
Global X Aging Population ETF
佔比3.31%
Acruence Active Hedge US Equity ETF
佔比2.58%
First Trust Indxx Medical Devices ETF
佔比2.23%
State Street SPDR S&P Health Care Equipment ETF
佔比1.88%
JPMorgan Healthcare Leaders ETF
佔比1.8%
PGIM Jennison Better Future ETF
佔比1.78%
ROBO Global Healthcare Technology & Innovation ETF
佔比1.73%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
May 07, 2020
Split
1→3
公告日期
除權除息日
類型
比率
May 07, 2020
Split
1→3
